The prostate is, engineering-wise, a plumbing problem. It is a walnut-sized gland that wraps around the urethra, and in a large share of men over 50 it grows - benign prostatic hyperplasia, BPH - until it squeezes the pipe and makes urinating an ordeal. The market's response to this has historically been a menu of somewhat grim options. You can take a pill every day, forever, and accept the side effects. You can have tissue heated with steam, or lasered, or cut out, which works but is a one-way door: you do not get that tissue back, and some men trade urinary relief for problems with sexual function. These are treatments that ask you to accept a trade-off.
Zenflow's entire pitch is that you shouldn't have to. The company, founded in 2014 out of Stanford's Biodesign program, spent roughly eleven years building a device called the Spring. It is a small coil made of nitinol - a nickel-titanium shape-memory alloy that "remembers" a shape and springs back to it - and the whole idea is almost aggressively simple. Instead of removing the obstruction, you hold the door open. The Spring props the urethra open from the inside, restoring flow while leaving the anatomy intact.
The best innovation here is not a new technology. It is the refusal to accept the trade-off everyone else accepted.
There are two things that make this more interesting than "startup builds smaller widget." The first is reversibility, which is a genuinely underrated feature in medicine. Most prostate procedures are permanent - once you've burned or removed the tissue, that's the deal. The Spring can be taken back out. This sounds like a footnote and is actually the whole conversation, because it changes the stakes of the decision a patient makes in a urologist's office. A permanent procedure is a big, scary yes. A reversible one is a small, low-cost yes. Lowering the cost of a decision can matter more than improving the outcome, and Zenflow engineered for the decision.
The company built its own scope
The second interesting thing is that Zenflow didn't just build the implant. It built the tool that delivers it. In medtech there's a recurring trap: your beautiful therapy is bottlenecked by the instrument that installs it. Zenflow's answer was to develop its own single-use, flexible cystoscope - the Spring Scope - and get it cleared by the FDA under a 510(k). The result is that the Spring is the first BPH therapy delivered via a flexible cystoscope, in an outpatient setting, without the operating room and general anesthesia that heavier procedures demand. When your therapy is limited by the tool, you either wait for someone else or you build the tool. Zenflow built the tool.
All of this would be a nice story if the numbers didn't hold, and the reason the FDA approved the device in December 2025 is that the numbers held. The pivotal study, called BREEZE, was the expensive, slow, correct version of a trial: prospective, multicenter, multinational, single-blinded, with a sham control arm. That sham arm is the unglamorous hero of the whole enterprise. BPH is a symptom-based condition, which means the placebo effect runs strong, which means the only way to prove your device does something real is to compare it against a convincing fake. Zenflow ran that version.
"Today's FDA approval marks the culmination of years of innovation."
What the data said
BREEZE reported a 60% responder rate at one year against 33% for sham - roughly double. Patients saw a 37% mean improvement in their International Prostate Symptom Score. Ninety-nine percent avoided a post-procedure catheter, which anyone who has worn one will tell you is not a small comfort. There were zero device-related serious adverse events, no deterioration in sexual function, and a 71% satisfaction rate. And - this is the number that quietly matters most - three-year durability data showed a sustained 74% responder rate. Anyone can show a device that works on day one. The BPH graveyard is full of implants that migrated or failed by year two. Durability is what earns a urologist's trust, and durability is boring and expensive to prove.
The people behind this are worth a line. Zenflow was co-founded by Nick Damiano and Shreya Mehta, the latter of whom started as an engineer, became CTO, and is now CEO - which is the classic and underrated founder arc in medtech, because the person selling the device to skeptical surgeons is also the person who can explain every design decision that went into it. Domain depth is a moat. The company traces its lineage to the Stanford Biodesign fellowship, a program built around a specific discipline: find the clinical need before you design anything. Not "here's our cool technology, what can it do," but "here's a problem millions of men have, what's the least invasive fix." The order matters more than founders like to admit.
It cost roughly $85 million and more than a decade to get here, across a Series A of $31.4 million and, most recently, a $24 million Series C in November 2024 to fund the FDA filing and commercial launch. That is a lot of money and a long time, and it is also exactly what implantable hardware costs, because you cannot ship a minimum-viable-product into someone's urethra and iterate. Some problems just take years and the patience to fund them. Zenflow, at last, has the approval to find out whether the market agrees that refusing the trade-off was worth the wait.
